Komori
Financial Results Presentation9267Genky DrugStores Co.,Ltd.Retail

Financial Results Briefing Materials for the Third Quarter of the Fiscal Year Ending June 2026

For the nine months ended March 2026, revenue increased 9.7% year on year and operating profit increased 17.3%. Revenue fell short of plan, while operating profit was in line with plan due to tight control of selling, general and administrative expenses.

Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1182
¥ million (year-on-year increase in operating profit, nine-month cumulative)
Wording
Conditional
How definitive the wording is.

No category-specific facts could be extracted from this document.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Some sales were pressured by the pullback from the surge in rice prices and the normalization of leafy vegetable prices, but customer traffic remained firm due to the price competitiveness of EDLP. Stable operation of self-checkout registers and the Management Partner system kept selling, general and administrative expenses, including personnel costs and utility expenses, below plan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Briefing Materials for the Third Quarter of the Fiscal Year Ending June 2026 | Genky DrugStores Co.,Ltd. (9267) timely disclosure | Komori